Search Results - "Lamivudine/adverse effects"

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials: week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Authors: Cahn P. Madero J. S. Arribas J. R. et al.

Contributors: Cahn P. Madero J. S. Arribas J. R. et al.

Source: The Lancet. 393:143-155

Subject Terms: Male, Lamivudine / therapeutic use, HIV Dolutegravir, Heterocyclic Compounds, 3-Ring / therapeutic use, Tenofovir / therapeutic use, HIV Infections, Viral Load / drug effects, Piperazines, 0302 clinical medicine, Emtricitabine / therapeutic use, Emtricitabine, Tenofovir/adverse effects, Lamivudine/adverse effects, Adult, Anti-HIV Agents, Anti-Retroviral Agents, Double-Blind Method, Drug Therapy, Combination, Female, HIV-1, Heterocyclic Compounds, 3-Ring, Humans, Lamivudine, Middle Aged, RNA, Viral, Tenofovir, Viral Load, Medicine (all), HIV Infections / virology, Heterocyclic Compounds, 3-Ring/adverse effects, 16. Peace & justice, Emtricitabine/adverse effects, Anti-Retroviral Agents / adverse effects, Anti-Retroviral Agents / therapeutic use, HIV-1 / isolation & purification, 3. Good health, [SDV] Life Sciences [q-bio], Anti-HIV Agents / adverse effects, Anti-HIV Agents / therapeutic use, Heterocyclic Compounds, 3-Ring / adverse effects, Tenofovir / adverse effects, Pyridones, HIV Infections/drug therapy, Lamivudine / adverse effects, Anti-Retroviral Agents/adverse effects, 03 medical and health sciences, Emtricitabine / adverse effects, SDG 3 - Good Health and Well-being, Oxazines, HIV-1/isolation & purification, RNA, Viral/blood, Viral Load/drug effects, HIV Infections / drug therapy, Anti-HIV Agents/adverse effects, RNA, Viral / blood

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/30420123
https://air.unimi.it/handle/2434/629086
https://www.sciencedirect.com/science/article/abs/pii/S0140673618324620#!
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32462-0/fulltext
https://research.monash.edu/en/publications/dolutegravir-plus-lamivudine-versus-dolutegravir-plus-tenofovir-d
https://iris.unimore.it/handle/11380/1221490
https://www.sciencedirect.com/science/article/abs/pii/S0140673618324620
https://biblio.vub.ac.be/vubir/(1ae261bf-adab-4c02-9192-55337e187a2e).html

Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study.

Authors: Post, F.A. Moyle, G.J. Stellbrink, H.J. et al.

Subject Terms: Adenine/administration & dosage, Adenine/adverse effects, Adolescent, Adult, Aged, Anti-HIV Agents/administration & dosage, Anti-HIV Agents/adverse effects, Benzoxazines/administration & dosage, Benzoxazines/adverse effects, Deoxycytidine/administration & dosage, Deoxycytidine/adverse effects, Dideoxynucleosides/administration & dosage, Dideoxynucleosides/adverse effects, Drug Combinations, Female, Glomerular Filtration Rate/drug effects, HIV Infections/drug therapy, HIV-1/isolation & purification, Humans, Kidney/drug effects, Lamivudine/administration & dosage, Lamivudine/adverse effects, Male, Middle Aged, Phosphonic Acids/administration & dosage, Phosphonic Acids/adverse effects, Retinol-Binding Proteins/urine, Treatment Outcome, Viral Load, Young Adult

Relation: Journal of Acquired Immune Deficiency Syndromes; 1944-7884[electronic], 1525-4135[linking]; https://iris.unil.ch/handle/iris/97997; serval:BIB_3CA002AEBD9B; 000281170500006

Availability: https://iris.unil.ch/handle/iris/97997
https://doi.org/10.1097/QAI.0b013e3181dd911e

Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.

Authors: Elzi, L. Marzolini, C. Furrer, H. et al.

Contributors: Elzi, L. Marzolini, C. Furrer, H. et al.

Subject Terms: AIDS-Related Opportunistic Infections/drug therapy, AIDS-Related Opportunistic Infections/epidemiology, Adenine/administration & dosage, Adenine/adverse effects, Adult, Anti-HIV Agents/administration & dosage, Anti-HIV Agents/adverse effects, Benzoxazines/administration & dosage, Benzoxazines/adverse effects, Deoxycytidine/administration & dosage, Deoxycytidine/adverse effects, Dideoxynucleosides/administration & dosage, Dideoxynucleosides/adverse effects, Drug Therapy, Combination, Female, HIV Infections/drug therapy, HIV Infections/epidemiology, Humans, Lamivudine/administration & dosage, Lamivudine/adverse effects, Lopinavir, Male, Middle Aged, Nevirapine/administration & dosage, Nevirapine/adverse effects, Oligopeptides/administration & dosage, Oligopeptides/adverse effects, Organophosphonates/administration & dosage, Organophosphonates/adverse effects

Relation: Archives of internal medicine; https://iris.unil.ch/handle/iris/253421; serval:BIB_FFDD9D2AEA04; 000273429200011

Availability: https://iris.unil.ch/handle/iris/253421
https://doi.org/10.1001/archinternmed.2009.432

Lactic acidosis and hyperlactatemia associated with lamivudine accumulation and sepsis in a kidney transplant recipient-a case report and review of the literature.

Authors: Hollinger, A. Cueni, N. Marzolini, C. et al.

Subject Terms: Acidosis, Lactic/chemically induced, Aged, Anti-HIV Agents/adverse effects, HIV Infections/complications, HIV Infections/drug therapy, Humans, Hyperlactatemia/chemically induced, Kidney Transplantation/adverse effects, Lamivudine/adverse effects, Male, Sepsis/drug therapy, AIDS, ART, Lactic acidosis, Lamivudine, Metabolic acidosis, NRTI

File Description: application/pdf

Relation: AIDS Research and Therapy; https://iris.unil.ch/handle/iris/137550; serval:BIB_693CB6DBA95A; 000693031800001

Availability: https://iris.unil.ch/handle/iris/137550
https://doi.org/10.1186/s12981-021-00382-8

Real-World Effectiveness, Tolerability, and Safety of Dolutegravir/Lamivudine in Korea

Contributors: Ki Hyun Lee Jinnam Kim Jung Ah Lee et al.

Subject Terms: Adult, Anti-HIV Agents* / adverse effects, HIV Infections* / drug therapy, HIV-1, Humans, Lamivudine / adverse effects, Republic of Korea, Retrospective Studies, Asia, HIV infection, dolutegravir/lamivudine, effectiveness, safety

Relation: VIRUSES-BASEL; J03792; https://ir.ymlib.yonsei.ac.kr/handle/22282913/192992; T202300399

Availability: https://ir.ymlib.yonsei.ac.kr/handle/22282913/192992
https://doi.org/10.3390/v14112558

Randomized trial of lamivudine versus entecavir in entecavir-treated patients with undetectable hepatitis B virus DNA: Outcome at 2 Years

Authors: James Fung John Yuen Wai-Kay Seto et al.

Source: Hepatology. 53:1148-1153

Subject Terms: Lamivudine - adverse effects - therapeutic use, Adult, Male, Guanine, Viral - analysis, Chronic - drug therapy - virology, 03 medical and health sciences, Hepatitis B, Chronic, 0302 clinical medicine, Drug Resistance, Viral, DNA, Viral - analysis, Humans, Alanine Transaminase - blood, Alanine Transaminase, DNA, Middle Aged, Viral Load, Hepatitis B, Guanine - analogs and derivatives - therapeutic use, 3. Good health, Treatment Outcome, Lamivudine, DNA, Viral, Female, Hepatitis B, Chronic - drug therapy - virology

Access URL: https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.24192
https://pubmed.ncbi.nlm.nih.gov/21480321
http://hub.hku.hk/handle/10722/137377
https://aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep.24192
https://core.ac.uk/display/37960473
http://onlinelibrary.wiley.com/doi/10.1002/hep.24192/full
http://hdl.handle.net/10722/137377

2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B

Authors: Cakaloglu, Y Chen, Y Papatheodoridis, G et al.

Source: Gastroenterology. 136:486-495

Subject Terms: Adult, Male, 0301 basic medicine, Hepatitis B virus, Adolescent, Global Health, Antiviral Agents, 03 medical and health sciences, Hepatitis B, Chronic, Double-Blind Method, Humans, Hepatitis B e Antigens, Longitudinal Studies, Prospective Studies, Aged, 0303 health sciences, Hepatitis B Surface Antigens, Antiviral Agents - adverse effects - pharmacology - therapeutic use, Chronic - blood - drug therapy, Lamivudine - adverse effects - pharmacology - therapeutic use, Alanine Transaminase, Nucleosides, Middle Aged, Hepatitis B, Hepatitis B, Chronic - blood - drug therapy, 3. Good health, Pyrimidinones - adverse effects - pharmacology - therapeutic use, Lamivudine, DNA, Viral, Female, Nucleosides - adverse effects - pharmacology - therapeutic use

Access URL: https://pubmed.ncbi.nlm.nih.gov/19027013
http://www.sciencedirect.com/science/article/pii/S0016508508018611
https://pubmed.ncbi.nlm.nih.gov/19027013/
https://www.gastrojournal.org/article/S0016508508018611/pdf
https://www.ncbi.nlm.nih.gov/pubmed/19027013
https://www.cabdirect.org/cabdirect/abstract/20093096724
https://europepmc.org/abstract/MED/19027013
http://hdl.handle.net/10722/59343

Antiretroviral therapy for pregnant women living with HIV or hepatitis B: a systematic review and meta-analysis

Authors: Siemieniuk, Reed A Foroutan, Farid Mirza, Reza et al.

Source: ISSN: 2044-6055 ; BMJ Open, vol. 7, no. 9 (2017) e019022.

Subject Terms: info:eu-repo/classification/ddc/618, Adult, Anti-Retroviral Agents/adverse effects/therapeutic use, Drug Combinations, Emtricitabine/adverse effects/therapeutic use, Female, HIV Infections/complications/drug therapy, Hepatitis B/complications/drug therapy, Humans, Infant, Infectious Disease Transmission, Vertical, Lamivudine/adverse effects/therapeutic use, Lopinavir/adverse effects/therapeutic use, Pregnancy, Pregnancy Complications, Infectious/drug therapy, Pregnancy Outcome, Ritonavir/adverse effects/therapeutic use, Tenofovir/adverse effects/therapeutic use, Young Adult, Zidovudine/adverse effects/therapeutic use

Relation: info:eu-repo/semantics/altIdentifier/pmid/28893758; unige:108128

Availability: https://archive-ouverte.unige.ch/unige:108128

Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B

Authors: Lai, Ching-Lung Gane, Edward Liaw, Yun-Fan et al.

Source: New England Journal of Medicine. 357:2576-2588

Subject Terms: Lamivudine - adverse effects - therapeutic use, Adult, Male, 0301 basic medicine, Hepatitis B virus, Adolescent, Genotype, Pyrimidinones, Antiviral Agents, Pyrimidinones - adverse effects - therapeutic use, 03 medical and health sciences, Hepatitis B, Chronic, Double-Blind Method, Antiviral Agents - adverse effects - therapeutic use, Drug Resistance, Viral, Humans, Hepatitis B e Antigens, Chronic - drug therapy, Aged, 0303 health sciences, Hepatitis B Surface Antigens, Nucleosides, Middle Aged, Hepatitis B, 3. Good health, Nucleosides - adverse effects - therapeutic use, Hepatitis B, Chronic - drug therapy, Lamivudine, DNA, Viral, Mutation, Female

Access URL: http://hub.hku.hk/bitstream/10722/57525/1/143339.pdf
https://pubmed.ncbi.nlm.nih.gov/18094378
https://www.nejm.org/doi/abs/10.1056/NEJMoa066422
http://hub.hku.hk/handle/10722/57525
https://www.ncbi.nlm.nih.gov/pubmed/18094378?access_num=18094378&link_type=MED
http://hub.hku.hk/bitstream/10722/57525/1/143339.pdf
https://www.nejm.org/doi/full/10.1056/NEJMoa066422
https://www.ncbi.nlm.nih.gov/pubmed/18094378
http://hdl.handle.net/10722/57525

Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis B

Authors: Robert G. Gish You Chen Chao Anna S. Lok et al.

Contributors: Robert G. Gish You Chen Chao Anna S. Lok et al.

Source: Gastroenterology. 133:1437-1444

Subject Terms: EMC MM-04-20-02-A, Hepatitis B virus, Guanine, Antiviral Agents/therapeutic use, Viral/blood, Antiviral Agents, Dose-Response Relationship, 03 medical and health sciences, Hepatitis B, Chronic, 0302 clinical medicine, SDG 3 - Good Health and Well-being, Double-Blind Method, Chronic/drug therapy, Guanine/analogs & derivatives, Humans, Lamivudine/therapeutic use, Hepatitis B e Antigens, Alanine Transaminase/blood, Lamivudine/adverse effects, Dose-Response Relationship, Drug, Guanine/therapeutic use, Alanine Transaminase, DNA, Hepatitis B virus/genetics, Hepatitis B, Antiviral Agents/adverse effects, Guanine/adverse effects, 3. Good health, Chronic/immunology, Lamivudine, DNA, Viral, Hepatitis B e Antigens/blood, Drug

File Description: 1437~1444

Access URL: https://pubmed.ncbi.nlm.nih.gov/17983800
https://pure.eur.nl/en/publications/d85c6616-33a6-4913-a383-8fd56a49d3a3
https://doi.org/10.1053/j.gastro.2007.08.025
https://mdanderson.elsevierpure.com/en/publications/entecavir-therapy-for-up-to-96-weeks-in-patients-with-hbeag-posit
http://ir.lib.ncku.edu.tw/handle/987654321/71972
https://yonsei.pure.elsevier.com/en/publications/entecavir-therapy-for-up-to-96-weeks-in-patients-with-hbeag-posit
https://www.gastrojournal.org/article/S0016-5085(07)01482-5/fulltext
https://www.sciencedirect.com/science/article/pii/S0016508507014825
https://pubmed.ncbi.nlm.nih.gov/17983800/

Adefovir Dipivoxil for Wait-Listed and Post–Liver Transplantation Patients with Lamivudine-Resistant Hepatitis B: Final Long-Term Results

Authors: Schiff E. Lai C. -L. Hadziyannis S. et al.

Contributors: Schiff E. Lai C. -L. Hadziyannis S. et al.

Source: Liver Transplantation. 13:349-360

Subject Terms: Male, Kidney Disease, Drug Resistance, Adefovir dipivoxil, wait-listed, liver transplantation, lamivudine-resistant, hepatitis B, Hepatitis B virus - genetics, Recurrence - prevention & control, 0302 clinical medicine, Antiviral Agents - adverse effects - therapeutic use, Organophosphonate, Secondary Prevention, Viral, Prospective Studies, Phosphonic Acids - adverse effects - therapeutic use, Hepatitis B viru, Middle Aged, Hepatitis B, 3. Good health, Waiting List, Lamivudine, Combination, Drug Therapy, Combination, Female, Kidney Diseases, Human, Lamivudine - adverse effects - therapeutic use, Adult, Hepatitis B virus, Adenine, Antiviral Agents, DNA, Viral, Drug Resistance, Viral, Humans, Liver Transplantation, Organophosphonates, Waiting Lists, Hepatitis B - blood - drug therapy - prevention & control, 03 medical and health sciences, Viral - blood, Drug Therapy, Kidney Diseases - chemically induced, antiviral therapy, hepatitis B virus, Adenine - adverse effects - analogs & derivatives - therapeutic use, Liver Transplantation - adverse effects - methods, Antiviral Agent, Transplantation, DNA, Prospective Studie, Surgery, DNA, Viral - blood

File Description: application/pdf; STAMPA

Access URL: https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lt.20981
https://pubmed.ncbi.nlm.nih.gov/17326221
https://europepmc.org/article/MED/17326221
https://hub.hku.hk/bitstream/10722/76418/1/re01.htm
http://onlinelibrary.wiley.com/doi/10.1002/lt.20981/abstract
http://hub.hku.hk/handle/10722/76418
https://dial.uclouvain.be/pr/boreal/object/boreal:164688
https://repub.eur.nl/pub/37049
https://hdl.handle.net/2434/39035
https://doi.org/10.1002/lt.20981
https://hdl.handle.net/10281/353711
https://doi.org/10.1002/lt.20981
https://hdl.handle.net/11380/1227481
https://doi.org/10.1002/lt.20981
https://hdl.handle.net/11573/450762
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000244609200008&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=0c7ff228ccbaaa74236f48834a34396a
https://doi.org/10.1002/lt.20981
http://hdl.handle.net/10722/76418

Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort

Authors: Calmy, Alexandra Pinoges, Lorextu Szumilin, Elisabeth et al.

Source: AIDS. 20:1163-1169

Subject Terms: Anti-HIV Agents / therapeutic use, Adult, Male, Lamivudine / therapeutic use, Anti-HIV Agents, Lamivudine / adverse effects, Medically Underserved Area, Stavudine / therapeutic use, HIV Infections, Antiretroviral Therapy, Highly Active / methods, Drug Administration Schedule, Drugs, Generic / administration & dosage, 03 medical and health sciences, Nevirapine / therapeutic use, 0302 clinical medicine, Antiretroviral Therapy, Highly Active, Reverse Transcriptase Inhibitors / adverse effects, Antiretroviral Therapy, Highly Active / adverse effects, Drugs, Generic, Humans, Nevirapine, Stavudine / administration & dosage, Nevirapine / adverse effects, Developing Countries, Reverse Transcriptase Inhibitors / therapeutic use, HIV Infections / drug therapy, Lamivudine / administration & dosage, CD4 Lymphocyte Count, 3. Good health, Reverse Transcriptase Inhibitors / administration & dosage, Drugs, Generic / therapeutic use, Stavudine, Treatment Outcome, Drugs, Generic / adverse effects, Nevirapine / administration & dosage, Lamivudine, Stavudine / adverse effects, Reverse Transcriptase Inhibitors, Female, Epidemiologic Methods, Anti-HIV Agents / adverse effects, Anti-HIV Agents / administration & dosage

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/16691068
http://core.ac.uk/display/9416695
http://journals.lww.com/00002030-200605120-00010
https://europepmc.org/article/MED/16691068
http://fieldresearch.msf.org/msf/handle/10144/18315
http://fieldresearch.msf.org/msf/bitstream/10144/18315/1/calmy.pdf
https://archive-ouverte.unige.ch/unige:173154
https://doi.org/10.1097/01.aids.0000226957.79847.d6

Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B

Authors: Fernandes, L Wilber, R Lok, AS et al.

Source: New England Journal of Medicine. 354:1011-1020

Subject Terms: Lamivudine - adverse effects - therapeutic use, Adult, Male, 0301 basic medicine, Hepatitis B virus, Guanine, Molecular Sequence Data, Drug Resistance, Hepatitis B e Antigens - blood, Medical sciences, Antiviral Agents, 03 medical and health sciences, Viral - blood, 0302 clinical medicine, Hepatitis B, Chronic, Double-Blind Method, Antiviral Agents - adverse effects - therapeutic use, Hepatitis B virus - genetics - isolation & purification, Drug Resistance, Viral, Chronic - blood - drug therapy - pathology, Humans, Viral, Hepatitis B e Antigens, Hepatitis B, Chronic - blood - drug therapy - pathology, Guanine - adverse effects - analogs & derivatives - therapeutic use, 0303 health sciences, Liver - pathology, DNA, Middle Aged, Hepatitis B, 3. Good health, Treatment Outcome, Liver, Lamivudine, DNA, Viral, Female, DNA, Viral - blood

File Description: 209717 bytes; 3020 bytes; application/pdf; text/plain

Access URL: http://hub.hku.hk/bitstream/10722/45018/1/125018.pdf
https://pubmed.ncbi.nlm.nih.gov/16525138
http://ir.lib.ncku.edu.tw/handle/987654321/90262
https://dl.uswr.ac.ir/handle/10722/45018
https://pubmed.ncbi.nlm.nih.gov/16525138/
http://ir.lib.ncku.edu.tw/bitstream/987654321/90262/1/7011100401037.pdf
http://www.ncbi.nlm.nih.gov/pubmed/16525138
https://www.nejm.org/doi/full/10.1056/NEJMoa051287
http://hdl.handle.net/10722/45018

Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B

Authors: Lau, George, K. K. Piratvisuth, Teerha Luo, Kang Xian et al.

Source: New England Journal of Medicine. 352:2682-2695

Subject Terms: Lamivudine - adverse effects - therapeutic use, Adult, Male, Hepatitis B virus, Adolescent, chronic - drug therapy, Interferon alpha-2, Hepatitis b, Antiviral Agents, Hepatitis B, Chronic, Polyethylene glycols - adverse effects - therapeutic use, Double-Blind Method, Drug Resistance, Viral, Humans, Antiviral agents - administration & dosage - adverse effects - therapeutic use, Hepatitis B e Antigens, Aged, Hepatitis B Surface Antigens, Interferon-alpha, 1103 Clinical Sciences, Alanine Transaminase, Middle Aged, 3. Good health, Hepatitis b, chronic - drug therapy, Lamivudine, DNA, Viral, Drug Therapy, Combination, Female, Interferon alfa-2a - adverse effects - therapeutic use

File Description: 3155 bytes; 176172 bytes; application/pdf; text/plain

Access URL: https://espace.library.uq.edu.au/view/UQ:167362/UQ167362_OA.pdf
https://pubmed.ncbi.nlm.nih.gov/15987917
https://www.nejm.org/doi/pdf/10.1056/NEJMoa043470
https://www.nejm.org/doi/abs/10.1056/NEJMoa043470
http://www.nice.org.uk/guidance/ta96/documents/roche-products-limited-cont2
https://pubmed.ncbi.nlm.nih.gov/15987917/
https://espace.library.uq.edu.au/view/UQ:167362/UQ167362_OA.pdf
https://europepmc.org/article/MED/15987917
http://hdl.handle.net/10722/43075

Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B

Authors: Marcellin, P Lau, GK Bonino, F et al.

Source: New England Journal of Medicine. 351:1206-1217

Subject Terms: Lamivudine - adverse effects - therapeutic use, Adult, Male, Hepatitis B virus, Adolescent, Interferon alpha-2, Hepatitis b, Antiviral Agents, Polyethylene Glycols, 12. Responsible consumption, 03 medical and health sciences, Hepatitis B, Chronic, 0302 clinical medicine, Polyethylene glycols - adverse effects - therapeutic use, Double-Blind Method, Humans, Hepatitis B e Antigens, Antiviral agents - adverse effects - therapeutic use, Aged, Interferon-alpha, Alanine Transaminase, Middle Aged, Recombinant Proteins, 3. Good health, Lamivudine, DNA, Viral, Drug Therapy, Combination, Female, Interferon alfa-2a - adverse effects - therapeutic use, Hepatitis b, chronic - blood - drug therapy - virology, chronic - blood - drug therapy - virology

File Description: 122021 bytes; 3155 bytes; application/pdf; text/plain

Access URL: http://hub.hku.hk/bitstream/10722/43076/1/100589.pdf
https://pubmed.ncbi.nlm.nih.gov/15371578
http://hub.hku.hk/handle/10722/43076
https://www.nejm.org/doi/full/10.1056/NEJMoa040431
https://arpi.unipi.it/handle/11568/87048
https://europepmc.org/article/MED/15371578
http://www.ncbi.nlm.nih.gov/pubmed/15371578
https://pubmed.ncbi.nlm.nih.gov/15371578/
https://hdl.handle.net/11584/12575
https://avesis.uludag.edu.tr/publication/details/f31e737b-dfb8-4d8a-a1bd-e11cc9e8720e/oai
http://hdl.handle.net/10722/43076

Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial

Authors: Laurent, Christian Kouanfack, Charles Koulla-Shiro, Sinata et al.

Source: The Lancet. 364:29-34

Subject Terms: Male, 0301 basic medicine, ESSAI CLINIQUE, HIV Infections, Drugs, Generic / administration & dosage, NEVIRAPINE, Acquired Immunodeficiency Syndrome / drug therapy, Cameroon, STAVUDINE, Nevirapine / adverse effects, ANALYSE STATISTIQUE, 0303 health sciences, HIV Infections / virology, SIDA, Anti-Retroviral Agents / administration & dosage, Acquired Immunodeficiency Syndrome / complications, Viral Load, Anti-Retroviral Agents / adverse effects, HIV-1 / isolation & purification, 3. Good health, Drug Combinations, Stavudine, Drugs, Generic / adverse effects, Anti-Retroviral Agents, Lamivudine, Disease Progression, VIRUS, Reverse Transcriptase Inhibitors, Female, HIV Infections / immunology, Adult, Lamivudine / adverse effects, LAMIVUDINE, TRAITEMENT MEDICAL, 03 medical and health sciences, Drugs, Generic, Humans, Nevirapine, EFFICACITE, Stavudine / administration & dosage, Developing Countries, Acquired Immunodeficiency Syndrome, MEDICAMENT, HIV Infections / drug therapy, Lamivudine / administration & dosage, CD4 Lymphocyte Count, TRITHERAPIE GENERIQUE, Reverse Transcriptase Inhibitors / administration & dosage, Nevirapine / administration & dosage, Stavudine / adverse effects, HIV-1

File Description: application/pdf; text/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/15234853
http://www.sciencedirect.com/science/article/pii/S0140673604165860
http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(04)16586-0.pdf
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(04)16586-0/fulltext
https://www.sciencedirect.com/science/article/pii/S0140673604165860
https://www.thelancet.com/journals/lancet/article/PIIS0140673604165860/abstract
https://europepmc.org/article/MED/15234853
http://www.documentation.ird.fr/hor/fdi:010033612

Long-term safety of lamivudine treatment in patients with chronic hepatitis B

Authors: Yao, GB Castiglia, M Gardner, SD et al.

Source: Gastroenterology. 125:1714-1722

Subject Terms: Adult, Male, 0301 basic medicine, Hepatitis B virus, Adolescent, Drug Resistance, Antiviral Agents, 03 medical and health sciences, Hepatitis B, Chronic, Antiviral Agents - adverse effects, Drug Resistance, Viral, Humans, Viral, Chronic - drug therapy, Lamivudine - adverse effects, Aged, Retrospective Studies, 0303 health sciences, Hepatitis B virus - drug effects - genetics, Middle Aged, Hepatitis B, 3. Good health, Hepatitis B, Chronic - drug therapy, Lamivudine, Mutation, Female

Access URL: https://pubmed.ncbi.nlm.nih.gov/14724824
https://www.sciencedirect.com/science/article/pii/S0016508503015294
http://www.ncbi.nlm.nih.gov/pubmed/14724824
http://hub.hku.hk/handle/10722/78550
https://miami.pure.elsevier.com/en/publications/long-term-safety-of-lamivudine-treatment-in-patients-with-chronic
https://core.ac.uk/display/37909085
https://pubmed.ncbi.nlm.nih.gov/14724824/
http://hdl.handle.net/10722/78550

Long-Term Efficacy, Safety, and Tolerability of Indinavir-Based Therapy in Protease Inhibitor--Naive Adults with Advanced HIV Infection

Authors: Hirsch, Martin S. Steigbigel, Roy T. Staszewski, Scholomo et al.

Source: Clinical Infectious Diseases, Vol. 37, No 8 (2003) pp. 1119-1124

Subject Terms: Adult, Diarrhea, Male, HIV Infections/ drug therapy, Anti-HIV Agents, HIV Infections, Indinavir, Zidovudine/adverse effects/ therapeutic use, RNA, Viral/metabolism, 03 medical and health sciences, Indinavir/adverse effects/therapeutic use, 0302 clinical medicine, Double-Blind Method, Anti-HIV Agents/adverse effects/therapeutic use, Humans, Lamivudine/adverse effects/therapeutic use, Fatigue, ddc:616, HIV Protease Inhibitors, Middle Aged, CD4 Lymphocyte Count, 3. Good health, HIV Protease Inhibitors/adverse effects/ therapeutic use, HIV-1/drug effects, Lamivudine, HIV-1, RNA, Viral, Diarrhea/etiology, Drug Therapy, Combination, Female, Fatigue/etiology, Zidovudine

File Description: application/pdf

Access URL: https://academic.oup.com/cid/article-pdf/37/8/1119/5911216/37-8-1119.pdf
https://pubmed.ncbi.nlm.nih.gov/14523778
https://www.jstor.org/stable/4483628
https://miami.pure.elsevier.com/en/publications/long-term-efficacy-safety-and-tolerability-of-indinavir-based-the
https://core.ac.uk/display/60954085
https://academic.oup.com/cid/article/37/8/1119/435376
http://www.ncbi.nlm.nih.gov/pubmed/14523778
https://archive-ouverte.unige.ch/unige:7317
https://archive-ouverte.unige.ch/unige:7317
https://doi.org/10.1086/378063
https://archive-ouverte.unige.ch/unige:7317
http://doc.rero.ch/record/292358/files/37-8-1119.pdf

Prevalence and Clinical Correlates of YMDD Variants during Lamivudine Therapy for Patients with Chronic Hepatitis B

Authors: Condreay, L Hunt, C Lai, CL et al.

Source: Clinical Infectious Diseases. 36:687-696

Subject Terms: Lamivudine - adverse effects - therapeutic use, Hepatitis B virus, Dna, viral - blood, Hepatitis b virus - drug effects - genetics - immunology, Alanine Transaminase, Dna, Antiviral Agents, 3. Good health, 03 medical and health sciences, Hepatitis B, Chronic, 0302 clinical medicine, viral - blood, Lamivudine, DNA, Viral, Drug Resistance, Viral, Prevalence, Humans, Hepatitis B e Antigens, Antiviral agents - adverse effects - therapeutic use, Alanine transaminase - blood

File Description: 3035 bytes; 198945 bytes; text/plain; application/pdf

Access URL: https://academic.oup.com/cid/article-pdf/36/6/687/905348/36-6-687.pdf
https://pubmed.ncbi.nlm.nih.gov/12627352
http://hub.hku.hk/handle/10722/42155
https://www.ncbi.nlm.nih.gov/pubmed/12627352
http://academic.oup.com/cid/article/36/6/687/318076
https://academic.oup.com/cid/article-pdf/36/6/687/905348/36-6-687.pdf
https://academic.oup.com/cid/article/36/6/687/318076
https://pubmed.ncbi.nlm.nih.gov/12627352/
http://hdl.handle.net/10722/42155

Comparison of the efficacy of lamivudine and famciclovir in Asian patients with chronic hepatitis B: Results of 24 weeks of therapy

Authors: Yuen, MF Lai, CL Lai, YP et al.

Source: Journal of Medical Virology. 67:334-338

Subject Terms: Lamivudine - adverse effects - therapeutic use, Adult, Male, 0301 basic medicine, China, Hepatitis B virus, Adolescent, Hepatitis B e Antigens - blood, Antiviral Agents, Hepatitis B virus - drug effects - isolation & purification - physiology, 03 medical and health sciences, Viral - blood, Hepatitis B, Chronic, Antiviral Agents - adverse effects - therapeutic use, Humans, Hepatitis B e Antigens, Chronic - drug therapy, Hepatitis B Antibodies, Hepatitis B Surface Antigens - blood, 2-Aminopurine, 0303 health sciences, Hepatitis B Surface Antigens, Famciclovir, DNA, Hepatitis B Antibodies - blood, Middle Aged, Hepatitis B, 3. Good health, Hepatitis B, Chronic - drug therapy, Treatment Outcome, Lamivudine, DNA, Viral, Female, DNA, Viral - blood, 2-Aminopurine - adverse effects - analogs & derivatives - therapeutic use

Access URL: https://pubmed.ncbi.nlm.nih.gov/12116023
http://hub.hku.hk/handle/10722/78223
http://europepmc.org/abstract/MED/12116023
https://onlinelibrary.wiley.com/doi/10.1002/jmv.10075
https://pubmed.ncbi.nlm.nih.gov/12116023/
https://www.ncbi.nlm.nih.gov/pubmed/12116023
https://core.ac.uk/display/37908901
http://hdl.handle.net/10722/78223